Invest
27 Years
4.4 Star
1 Crore +
IOL Chemicals and Pharmaceuticals announced Q4FY24 & FY24 results:
Q4FY24 Financial Highlights:
- Total income at Rs 511 crore against Rs 596 crore
- EBITDA at Rs 57.6 crore against Rs 104.5 crore
- Net profit at Rs 28.2 crore against Rs 65.3 crore
FY24 Financial Highlights:
- Total income at Rs 2,162.9 crore against Rs 2,242.7 crore
- EBITDA up 3.8% YoY to Rs 261.6 crore
- Net profit at Rs 135 crore against Rs 140 crore
Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The Company has exhibited resilient financial performance in FY24 despite challenging macro-economic environment and volatile chemical sector trajectory. We are receiving positive response in export market despite geopolitical uncertainties and supply chain obstacles. Though, the revenue growth has been sluggish, the margins were stable following Company’s sustained cost control initiatives. We believe that chemical sector turbulence would likely stabilize this financial year. In the nonIbuprofen segment, we are on track to expand our footprints in key regulated markets following approvals and certifications received last year. During the year the capex in infrastructure and automization will improve the operational efficiency and reduce the carbon footprint.”
FAQ’s on IOL Chemicals & Pharmaceuticals Ltd Shares
